Merz Pharma GmbH & Co. KGaA is an innovative and international healthcare company with its own research and development department. It focuses on drugs for the treatment of illness in the fields of neurology and psychiatry. The company is bundling the activities of its subsidiaries Merz Pharmaceuticals, Merz Consumer Care, Merz Dental, and Merz Hygiene, with products ranging from prescription drugs and OTC products for health and wellness, materials for dentists and dental technicians to hygienic products for medical disinfection and cleaning.\nThe units of Merz Group Services, the fith Merz subsidiary, include Human Resources, Supply Chain/Purchasing, Information Technology (IT), Technical Operations and Finances/Controlling.

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Fuso Pharmaceutical Industries, Ltd. engages in the manufacture and sale of ethical pharmaceutical and medical equipment. It operates through the Pharmaceuticals and Real Estate divisions. The Pharmaceuticals division deals with the manufacture and sale of pharmaceutical products which mainly focus on prescription drugs, infusions, and artificial kidney dialysis solutions. The Real Estate division handles leasing of real estate properties. The company was founded on March 25, 1937 and is headquartered in Osaka, Japan.

Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert in 1950 and headquartered in Irvine, CA.

RespireRx Pharmaceuticals Inc. is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. All of the Company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress.

Nuovo Biologics, L.L.C. engages in the research and development of animal health products. It develops PANAVIRA, an antiviral drug derived from natural sources that is used for the treatment of various viral related diseases in non-consumable animals, such as cats, dogs, birds, and horses. The company was incorporated in 2010 and is based in Miami, Florida.

The Kenneth S. Warren Institute is a not-for-profit organization based in Durham, North Carolina that as of 2017 appears to be defunct. It had been based in Tarrytown, New York, and in 2001, the institute bought a 15-acre (61,000 m²) campus located in Westchester County, New York from the Kitchawan Institute. At that time its director and lead researcher was Anthony Cerami, and it was a medical research institute that had been doing research related to erythropoietin derivatives they called "tissue protective cytokines". They also said that they coordinated with researchers who were working on vaccines for neglected tropical diseases. Cerami has been president and trustee of an organization called the "Kenneth S. Warren Laboratories, Inc." as of March 1998.

IntegraGen is a French biotech company based on the Genopole life science park in Evry, near Paris. It leverages its unique intellectual property, research expertise and privileged access to sample libraries to develop molecular markers for central nervous system and metabolic diseases. IntegraGen notably uses its proprietary technology platforms to provide genomics services to the pharmaceutical industry, biotech firms and other research providers.

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

BTG acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. British Technology Group International that began operation in 1948 became BTG in March 1995. Its headquarters is in London in the United Kingdom.

Part of Ipsen SA, Ipsen Biopharm Ltd. is a company headquartered in Wrexham, UK, that manufactures pharmaceutical products. It was founded in 1982.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Abbott Products SAS provides pharmaceutical products. The company is headquartered in Suresnes, France.

Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd., established on 2009-04-14, Business scope includes general business items:Bioengineering products,medicine,Health products,cosmetic,Fine Chemicals,Technology development of medical device products,technology transfer(law,Except for projects that are required to be approved before registration by administrative regulations or decisions of the State Council);Fine Chemicals,Chemical raw materials,chemical reagent(Does not contain dangerous goods),glassware,Sales of instrumentation,Other domestic trade;Operating import and export business(None of the above is legal,Administrative regulations,The State Council decides to specify items that require pre-approval and prohibition).,The licensing program is:

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the potential treatment of lupus nephritis, focal segmental glomerulosclerosis, and Dry Eye Syndrome.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Allergan Sales LLC wholesales pharmaceutical products. It is a wholly-owned subsidiary of Allergan, Inc. The company is located in Englewood. CO